Results for the 2024/2025 financial year
Damartex continues its operational recovery and is committed to strengthening its commercial momentum.
PERFORMANCE BY pole
Damartex concluded the 2024/25 fiscal year with revenue of €521,2Mn, remaining nearly stable compared to the previous year (-0.6% at constant exchange rates, -1.1% at actual exchange rates). In a persistently challenging market environment, the Group has stabilized its revenue after three years of decline and confirmed the momentum of profitability recovery initiated last year.
The “Fashion” division’s revenue for the 2024/2025 fiscal year stands at
€389.4 Mn, reflecting a slight decline of -1.7% at actual exchange rates (-2.2% at constant exchange rates) amid a challenging environment. While the Damart brand experienced a modest decrease in revenue (-2.4% at actual exchange rates), the Xandres label recorded an annual revenue increase of +5.7% at actual exchange rates. EBITDA of Fashion division reached €13,3Mn, marking a significant rise that underscores Damart’s solid fundamentals, the strategic positioning of Xandres, and the Group’s ongoing efforts to enhance the profitability of the division’s brands.
The “Home & Lifestyle” division reported annual revenue of €102.7Mn, reflecting a real exchange rate growth of +3.5%. Amid significant sectoral changes, investments in digital channels and product range renewal facilitated the acquisition of new customers. However, the Group has yet to realize the anticipated benefits for this division, resulting in a slight decline in EBITDA compared to the previous year, closing at €-1.7Mn.
The “Healthcare” division reports annual revenue of €29.1Mn, representing a +1.6% increase at constant and real exchange rates, driven by the growth momentum of Santéol and the encouraging results from Almadia following the strategic repositioning of its service activities initiated in the previous fiscal year. The Healthcare division’s EBITDA stands at €4.2Mn, showing a slight decline compared to the previous year.
FINANCIAL RESULTS
Damartex’s operational EBITDA shows a significant improvement, reaching €15.8Mn compared to €12.2Mn last year, representing an increase of +28.8%. This reflects stringent and agile cost management across all divisions to achieve sustainable growth. The Group closes the 2024/25 fiscal year with a net result of €-17.7Mn, demonstrating considerable improvement but still reflecting the impact of financing costs on the fiscal year.
FINANCIAL POSITION
The net financial position stands at €-119,6Mn as of the end of June 2025 (compared to €-104.7Mn as of the end of June 2024), reflecting the debt burden and ongoing investments necessary for the Group’s transformation.
The working capital requirement is €23.1Mn as of the end of June 2025, remaining stable compared to the previous fiscal year. This outcome confirms the sound management executed by the Group’s teams.
DIVIDEND
The Executive Board will not propose the distribution of dividends at the General Meeting scheduled for November 20, 2025.
PERSPECTIVES
Fully committed to its ambition of becoming a European benchmark in the Silver Economy, Damartex is advancing the second phase of its strategic plan DARE.ACT.IMPACT 2026, structured around four key complementary pillars:
• Delivering Financial Performance: The Group is beginning to realize the benefits of the restructuring undertaken and continues its implementation, consistently focused on enhancing the operational profitability of its divisions.
• Innovative Brand Experience: The teams are advancing brand development and omnichannel innovation to refine the customer-patient experience.
• Change Our World: Aware of its societal responsibility, Damartex is actively pursuing the reduction of its carbon footprint. • Shared Leadership: Initiated in 2023/2024, the implementation of an innovative leadership approach focused on autonomy and shared responsibility is progressing, aiming to enhance adaptability and ensure transparent communication.
“Damartex continues to shape its legacy: that of a Group that meets challenges head-on and transforms obstacles into opportunities. Thanks to the dedication and professionalism of our teams, we are strengthening our core foundations while paving the way for new prospects. Our ambition is clear: to combine performance with a positive impact, serving the clients and patients who place their trust in us,” states Nicolas Marchand, CEO of the Damartex Group.